Nichols & Pratt Advisers LLP Novo Nordisk A S Transaction History

Nichols & Pratt Advisers LLP

$1.5 Billion
Q3 2024

A detailed history of Nichols & Pratt Advisers LLP transactions in Novo Nordisk A S stock. As of the latest transaction made, Nichols & Pratt Advisers LLP holds 488,210 shares of NVO stock, worth $50.1 Million. This represents 3.87% of its overall portfolio holdings.

Number of Shares

488,210

Previous 496,215 1.61%

Holding current value

$50.1 Million

Previous $70.8 Million 17.93%

% of portfolio

3.87%

Previous 4.9%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	SELL	$119.07 - $145.42 $953,155 - $1.16 Million	-8,005 Reduced 1.61%	488,210 $58.1 Million
Q2 2024 Jul 25, 2024	SELL	$122.71 - $146.91 $37,426 - $44,807	-305 Reduced 0.06%	496,215 $70.8 Million
Q1 2024 Apr 29, 2024	SELL	$102.11 - $135.92 $620,828 - $826,393	-6,080 Reduced 1.21%	496,520 $63.8 Million
Q4 2023 Feb 07, 2024	SELL	$87.78 - $105.45 $567,058 - $681,207	-6,460 Reduced 1.27%	502,600 $52 Million
Q3 2023 Nov 09, 2023	BUY	$90.94 - $199.54 $23 Million - $50.5 Million	253,140 Added 98.91%	509,060 $46.3 Million
Q2 2023 Aug 02, 2023	SELL	$155.98 - $172.65 $321,474 - $355,831	-2,061 Reduced 0.8%	255,920 $41.4 Million
Q1 2023 May 03, 2023	SELL	$132.34 - $159.14 $503,686 - $605,686	-3,806 Reduced 1.45%	257,981 $41.1 Million
Q4 2022 Feb 03, 2023	SELL	$102.55 - $135.33 $45,122 - $59,545	-440 Reduced 0.17%	261,787 $35.4 Million
Q3 2022 Nov 01, 2022	SELL	$95.28 - $116.93 $93,850 - $115,176	-985 Reduced 0.37%	262,227 $26.1 Million
Q2 2022 Aug 04, 2022	SELL	$103.24 - $121.81 $47,490 - $56,032	-460 Reduced 0.17%	263,212 $29.3 Million
Q1 2022 May 10, 2022	BUY	$93.1 - $112.54 $4,655 - $5,627	50 Added 0.02%	263,672 $29.3 Million
Q4 2021 Feb 08, 2022	SELL	$95.88 - $117.08 $26,367 - $32,197	-275 Reduced 0.1%	263,622 $29.5 Million
Q3 2021 Nov 01, 2021	SELL	$84.42 - $106.62 $3,798 - $4,797	-45 Reduced 0.02%	263,897 $25.3 Million
Q2 2021 Aug 09, 2021	BUY	$67.66 - $84.76 $11,163 - $13,985	165 Added 0.06%	263,942 $22.1 Million
Q1 2021 May 11, 2021	SELL	$67.06 - $75.82 $35,877 - $40,563	-535 Reduced 0.2%	263,777 $17.8 Million
Q4 2020 Feb 08, 2021	SELL	$63.89 - $73.8 $51,175 - $59,113	-801 Reduced 0.3%	264,312 $18.5 Million
Q3 2020 Nov 10, 2020	BUY	$63.69 - $70.22 $48,277 - $53,226	758 Added 0.29%	265,113 $18.4 Million
Q2 2020 Aug 10, 2020	SELL	$58.54 - $67.94 $81,077 - $94,096	-1,385 Reduced 0.52%	264,355 $17.3 Million
Q1 2020 Apr 24, 2020	BUY	$49.46 - $64.78 $89,720 - $117,510	1,814 Added 0.69%	265,740 $16 Million
Q4 2019 Feb 07, 2020	SELL	$49.86 - $58.26 $102,960 - $120,306	-2,065 Reduced 0.78%	263,926 $15.3 Million
Q3 2019 Nov 07, 2019	BUY	$47.54 - $53.43 $746,140 - $838,583	15,695 Added 6.27%	265,991 $13.7 Million
Q2 2019 Aug 05, 2019	BUY	$46.79 - $52.47 $187,300 - $210,037	4,003 Added 1.63%	250,296 $12.8 Million
Q1 2019 Apr 30, 2019	BUY	$46.36 - $52.63 $290,352 - $329,621	6,263 Added 2.61%	246,293 $12.9 Million
Q4 2018 Feb 08, 2019	BUY	$41.54 - $47.25 $403,104 - $458,514	9,704 Added 4.21%	240,030 $11.1 Million
Q3 2018 Nov 05, 2018	BUY	$46.76 - $51.24 $295,569 - $323,888	6,321 Added 2.82%	230,326 $10.8 Million
Q2 2018 Jul 27, 2018	BUY	$44.29 - $50.42 $336,604 - $383,192	7,600 Added 3.51%	224,005 $10.3 Million
Q4 2017 Feb 09, 2018	BUY	$47.53 - $53.73 $21,388 - $24,178	450 Added 0.21%	216,405 $11.6 Million
Q3 2017 Nov 08, 2017	SELL	$41.15 - $49.22 $41,150 - $49,220	-1,000 Reduced 0.46%	215,955 $10.4 Million
Q2 2017 Aug 08, 2017	BUY	N/A	216,955	216,955 $9.3 Million

Others Institutions Holding NVO

# of Institutions

1,954

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $232B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nichols & Pratt Advisers LLP , based on Form 13F filings with the SEC.

News

Stay updated on Nichols & Pratt Advisers LLP with notifications on news.

Account

Nichols & Pratt Advisers LLP Novo Nordisk A S Transaction History